| Literature DB >> 22043956 |
Luigi Buonaguro1, Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro.
Abstract
Virus-like particles hold great promise for the development of effective and affordable vaccines. Indeed, virus-like particles are suitable for presentation and efficient delivery of linear as well as conformational antigens to antigen-presenting cells. This will ultimately result in optimal B-cell activation and cross-presentation with both MHC class I and II molecules to prime CD4(+) T-helper as well as CD8(+) cytotoxic T cells. This article provides an update on the development and use of virus-like particles as vaccine approaches for infectious diseases and cancer.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22043956 DOI: 10.1586/erv.11.135
Source DB: PubMed Journal: Expert Rev Vaccines ISSN: 1476-0584 Impact factor: 5.217